Increases in plasma concentration of m-chlorophenylpiperazine, but not trazodone, with low-dose haloperidol
- PMID:9029745
- DOI: 10.1097/00007691-199702000-00007
Increases in plasma concentration of m-chlorophenylpiperazine, but not trazodone, with low-dose haloperidol
Abstract
Our previous study suggested that cytochrome P4502D6 (CYP2D6) is involved in the metabolism of trazodone and its active metabolite, m-chlorophenylpiperazine (m-CPP). The purpose of this study was to examine the degrees of increase in plasma concentrations of trazodone and m-CPP induced by haloperidol, which is an inhibitor of CYP2D6. The subjects were nine depressed inpatients receiving trazodone at bedtime (150 mg in seven patients and 300 mg in two) for 2-19 weeks. Haloperidol at 4 mg/day was coadministered for 1 week, and blood samplings were taken before and after the coadministration. Contrary to our expectation, haloperidol did not significantly increase the mean plasma trazodone concentration (810 +/- 382 vs. 856 +/- 357 ng/ml). However, haloperidol significantly increased (p < 0.01) the mean plasma m-CPP concentration (78 +/- 31 vs. 92 +/- 34 ng/ml).
Similar articles
- Inhibition of trazodone metabolism by thioridazine in humans.Yasui N, Otani K, Kaneko S, Ohkubo T, Osanai T, Ishida M, Mihara K, Kondo T, Sugawara K, Fukushima Y.Yasui N, et al.Ther Drug Monit. 1995 Aug;17(4):333-5. doi: 10.1097/00007691-199508000-00003.Ther Drug Monit. 1995.PMID:7482685
- Relationship between plasma concentrations of trazodone and its active metabolite, m-chlorophenylpiperazine, and its clinical effect in depressed patients.Mihara K, Yasui-Furukori N, Kondo T, Ishida M, Ono S, Ohkubo T, Osanai T, Sugawara K, Otani K, Kaneko S.Mihara K, et al.Ther Drug Monit. 2002 Aug;24(4):563-6. doi: 10.1097/00007691-200208000-00016.Ther Drug Monit. 2002.PMID:12142643Clinical Trial.
- Relationship between the CYP2D6 genotype and the steady-state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine.Mihara K, Otani K, Suzuki A, Yasui N, Nakano H, Meng X, Ohkubo T, Nagasaki T, Kaneko S, Tsuchida S, Sugawara K, Gonzalez FJ.Mihara K, et al.Psychopharmacology (Berl). 1997 Sep;133(1):95-8. doi: 10.1007/s002130050376.Psychopharmacology (Berl). 1997.PMID:9335086
- Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.Swainston Harrison T, Perry CM.Swainston Harrison T, et al.Drugs. 2004;64(15):1715-36. doi: 10.2165/00003495-200464150-00010.Drugs. 2004.PMID:15257633Review.
- Clinical pharmacokinetics of nefazodone.Greene DS, Barbhaiya RH.Greene DS, et al.Clin Pharmacokinet. 1997 Oct;33(4):260-75. doi: 10.2165/00003088-199733040-00002.Clin Pharmacokinet. 1997.PMID:9342502Review.
Cited by
- Does trazodone have a role in palliating symptoms?Davis MP.Davis MP.Support Care Cancer. 2007 Feb;15(2):221-4. doi: 10.1007/s00520-006-0111-0. Epub 2006 Nov 28.Support Care Cancer. 2007.PMID:17131134
- Potent inhibition of CYP2D6 by haloperidol metabolites: stereoselective inhibition by reduced haloperidol.Shin JG, Kane K, Flockhart DA.Shin JG, et al.Br J Clin Pharmacol. 2001 Jan;51(1):45-52. doi: 10.1046/j.1365-2125.2001.01313.x.Br J Clin Pharmacol. 2001.PMID:11167668Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources